Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR

Healthcare Psychedelics
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

PR Newswire January 25, 2022

MindMed Enrolls First Participant in a Study of its Session Monitoring System

PR Newswire January 18, 2022

IIROC Trade Resumption - MMED

PR Newswire January 17, 2022

IIROC Trading Halt - MMED

PR Newswire January 17, 2022

Stephen Hurst Resigns from MindMed Board of Directors

PR Newswire January 7, 2022

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

PR Newswire January 4, 2022

MindMed to Participate at the LifeSci Partners 11th Annual Corporate Access Event

PR Newswire December 30, 2021

MindMed Announces Transitions to Management Team

PR Newswire December 29, 2021

MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder

PR Newswire December 21, 2021

MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

PR Newswire December 17, 2021

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

PR Newswire December 14, 2021

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

PR Newswire December 9, 2021

MindMed to Participate at the Benzinga Global Small Cap Conference

PR Newswire December 2, 2021

MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

PR Newswire December 1, 2021

MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

PR Newswire November 30, 2021

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

PR Newswire November 16, 2021

MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline

PR Newswire November 15, 2021

MindMed to Present at the Jefferies London Healthcare Conference

PR Newswire November 12, 2021

MindMed Appoints Dr. Maria Oquendo to its Scientific Advisory Board

PR Newswire November 5, 2021

MindMed to Present at Web Summit on Future of Mental Health

PR Newswire November 1, 2021